Can (99)Tc(m)-3PRGD(2)(α(ν)β(3)) and (18)F-FDG dual-tracer molecular imaging change the therapeutic strategy for progressive refractory differentiated thyroid cancer: Case report

The management of radioiodine refractory differentiated thyroid cancer (RAIR-DTC) represents a major challenge in thyroid cancer. The American Thyroid Association guidelines recommend the use of tyrosine kinase inhibitors (TKIs) for RAIR-DTC that does not respond to conventional treatment. Currently...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu, Li, Yuxuan, Lin, Zhiyi, Chen, Wenxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
6800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901998/
https://www.ncbi.nlm.nih.gov/pubmed/36749225
http://dx.doi.org/10.1097/MD.0000000000032751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901998/
https://www.ncbi.nlm.nih.gov/pubmed/36749225
http://dx.doi.org/10.1097/MD.0000000000032751

Ejemplares similares